KA
IBRX icon

KLCM Advisors’s ImmunityBio IBRX Stock Holding History

KLCM Advisors’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$222K Buy
+29,000
New +$199K 0.02% 241

Other funds holding IBRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

KLCM Advisors's IBRX Position: Q1 2026 in Review

KLCM Advisors opened a new position in ImmunityBio (IBRX) in Q1 2026: 29,000 shares worth $222K. The stake represents 0.02% of the portfolio and ranks #241 among its holdings.

386 funds tracked by Wall St. Rank hold IBRX as of Q1 2026.

  • KLCM Advisors held 29,000 shares of ImmunityBio worth $222K as of Q1 2026.
  • ImmunityBio was a new KLCM Advisors position in Q1 2026.
  • ImmunityBio made up 0.02% of KLCM Advisors's portfolio in Q1 2026, its #241 holding.
  • 386 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2026.

Based on KLCM Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.